Similar articles

• Cellular immunotherapy of cancer.

  Topalian SL, Rosenberg SA. Topalian SL, et al. Crit Care Med. 1990 Feb;18(2 Suppl):S144. Crit Care Med. 1990. PMID: 2298029 No abstract available.
• Interleukin 2 in cancer therapy.

  Testa U, Montesoro E, Bulgarini D, Samoggia P, Masciulli R, Habetswallner D, Carè A, Mariani G, Giannella G, Boccoli G, et al. Testa U, et al. Ann Ist Super Sanita. 1990;26(3-4):283-334. Ann Ist Super Sanita. 1990. PMID: 2091501 Review.
• Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.

  Rosenberg SA. Rosenberg SA. Important Adv Oncol. 1988:217-57. Important Adv Oncol. 1988. PMID: 3042605 Review. No abstract available.
• Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC).

  Oldham RK, Lewko WM, Good RW, Sharp E. Oldham RK, et al. In Vivo. 1994 Nov-Dec;8(5):653-63. In Vivo. 1994. PMID: 7537108 Review.
• [Interleukin-2].

  Bijvank E, van Loo J. Bijvank E, et al. TVZ. 1988 Mar 3;42(5):154-7. TVZ. 1988. PMID: 3128894 Dutch. No abstract available.